ReviewAmerican journal of therapeutics
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
Review in American journal of therapeutics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials.Frontiers in neurology · 2024Pooled it
- Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).Obesity (Silver Spring, Md.) · 2012Trial
- Antiobesity Pharmacotherapy for Patients With Genetic Obesity Due to Defects in the Leptin-Melanocortin Pathway.Endocrine reviews · 2025Review
- Adipose Tissue, Non-Communicable Diseases, and Physical Exercise: An Imperfect Triangle.International journal of molecular sciences · 2023Review
- The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics.Psychiatry investigation · 2023Article
- Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding.Neuropsychiatric disease and treatment · 2023Review
- Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control.International journal of molecular sciences · 2022Review
- Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy.Children (Basel, Switzerland) · 2022Review
- Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.Frontiers in psychiatry · 2022Article
- Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.Seminars in liver disease · 2021Review
- Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.The world journal of men's health · 2021Review
- The Triple Combination Phentermine Plus 5-HTP/Carbidopa Leads to Greater Weight Loss, With Fewer Psychomotor Side Effects Than Each Drug Alone.Frontiers in pharmacology · 2019Article
- Assessing Allosteric Modulation of CBMethods in enzymology · 2017Article
- A systematic investigation of the differential roles for ventral tegmentum serotonin 1- and 2-type receptors on food intake in the rat.Brain research · 2016Article
- Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse.Journal of toxicologic pathology · 2016Review
- Serotonergic versus nonserotonergic dorsal raphe projection neurons: differential participation in reward circuitry.Cell reports · 2014Article
- On the value of seasonal mammals for identifying mechanisms underlying the control of food intake and body weight.Hormones and behavior · 2014Review
- Serotonin 1A, 1B, and 7 receptors of the rat medial nucleus accumbens differentially regulate feeding, water intake, and locomotor activity.Pharmacology, biochemistry, and behavior · 2013Article
- Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The prevalence of obesity in the United States is a major health problem associated with significant morbidity, mortality, and economic burden. Although obesity and drug addiction are typically considered distinct clinical entities, both diseases involve dysregulation of biogenic amine neuron systems in the brain. Thus, research efforts to develop medications for treating drug addiction can contribute insights into the pharmacotherapy for obesity. Here, we review the neurochemical mechanisms of selected stimulant medications used in the treatment of obesity and issues related to fenfluramine-associated cardiac valvulopathy. In particular, we discuss the evidence that cardiac valve disease involves activation of mitogenic serotonin 2B (5-HT2B) receptors by norfenfluramine, the major metabolite of fenfluramine. Advances in medication discovery suggest that novel molecular entities that target 2 different neurochemical mechanisms, that is, "combination pharmacotherapy," will yield efficacious antiobesity medications with reduced adverse side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.